Pyrrolo[2,3-d]Pyrimidines as Kinase Inhibitors

Title:Pyrrolo[2,3-d]Pyrimidines as Kinase Inhibitors

Volume: 24 Issue: 19

Author(s): Francesca Musumeci, Monica Sanna, Giancarlo Grossi, Chiara Brullo, Anna Lucia Fallacara and Silvia Schenone*

Affiliation:

• Dipartimento di Scienze Farmaceutiche, Università degli Studi di Genova, Viale Benedetto XV, 3, I-16132, Genova,Italy

Keywords: Pyrrolo[2, 3-d]pyrimidine, kinase inhibitors, patents, anticancer agents, anti-inflammatory agents.

Abstract: The pyrrolo[2,3-d]pyrimidine nucleus is a deaza-isostere of adenine, the nitrogenous base of ATP, and is present in many ATP-competitive inhibitors of different kinases. In the last few years the number of articles and patents that have appeared involving this type of inhibitors has dramatically increased and some compounds have been approved for the treatment of inflammatory or myeloproliferative diseases. Other derivatives are currently being evaluated in clinical trials. This review deals with pyrrolo[2,3- d]pyrimidine derivatives active as kinase inhibitors that have been reported in the literature from 2011 to 2016, with a particular interest on the recently patented compounds. The molecules are classified depending on the inhibited kinase, focusing on their chemical structures.

Cite this article as:

Musumeci Francesca , Sanna Monica , Grossi Giancarlo , Brullo Chiara, Fallacara Lucia Anna and Schenone Silvia *, Pyrrolo[2,3-d]Pyrimidines as Kinase Inhibitors, Current Medicinal Chemistry 2017; 24 (19) . https://dx.doi.org/10.2174/0929867324666170303162100